Lanadelumab (Takhzyro®) is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/03/2019|
|Rapid review completed||23/05/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lanadelumab compared with the current standard of care.|